StockData
GRI Bio, Inc. logo

GRI Bio, Inc. (GRI) stock

GRINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$1.27−0.08 (-5.95%)

Close on Nov 18, 2026Market cap $2.78MP/E –Yield –

GRI Bio revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

GRI Bio's revenue for the twelve months ending Mar 31, 2022 was $0. For fiscal 2021 it was $0, down 100.0% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2021Dec 31, 2021$0-100.0%
FY2020Dec 31, 2020$100.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2022Mar 31, 2022$0–
Q4 FY2021Dec 31, 2021$0–
Q3 FY2021Sep 30, 2021$0–
Q2 FY2021Jun 30, 2021$0–
Q1 FY2021Mar 31, 2021$0-100.0%
Q4 FY2020Dec 31, 2020$0–
Q3 FY2020Sep 30, 2020$0–
Q2 FY2020Jun 30, 2020$0–
Q1 FY2020Mar 31, 2020$100.00K–

More GRI Bio figures

See a number that looks wrong?